Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
BeOne's degrader BG-60366 appears to have been discontinued.
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Daraxonrasib scores a plenary session late-breaker.
The disclosure comes as another of Arcus's TIGIT trials flops.
